A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep
A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep
复制标题
DOI：
10.1016/j.vaccine.2010.04.102
复制
发表时间：
2010-07-05
期刊：
影响因子：
5.5
通讯作者：
Bu, Zhigao
中科院分区：
文献类型：
--
作者：
Chen, Weiye;Hu, Sen;Bu, Zhigao
重组羊痘病毒 (CPV) 是一种很有前景的候选病毒，可区分已接种动物 (DIVA) 和小反刍兽疫 (PPR) 感染的疫苗。为了使重组CPV在现场成功使用，应该有可靠的疫苗产品质量控制、监测和疫苗接种评价指标。病毒中和抗体 (VNA) 与针对 PPR 的保护相关，并且是用于此目的的技术上可行的指标。然而，这种载体疫苗在山羊和绵羊中的免疫原性尚未得到充分评估。在本研究中，我们生成了两种重组 CPV 病毒，rCPV-PPRVH 和 rCPV-PPRVF，分别表达 PPR 病毒 (PPRV) 糖蛋白 H 和 F。不同剂量重组病毒的疫苗接种研究表明，rCPV-PPRVH 是比 rCPV-PPRVF 更有效的 PPRV VNA 诱导剂。一剂 rCPV-PPRVH 足以使 80% 的免疫羊发生血清转化。第二剂诱导显着更高的 PPRV VNA 滴度。山羊和绵羊之间的 PPRV VNA 反应没有显着差异。皮下接种也诱导了显着的 PPRV VNA 反应。超过 80% 的已接种疫苗的山羊和绵羊体内可检测到 PPRV VNA 长达 6 个月以上。每隔 6 个月加强疫苗接种可在山羊和绵羊中诱导 PPRV VNA 的显着再加强功效。此外，两剂rCPV-PPRVH可以完全克服动物体内已有的对CPV疫苗骨架的免疫力造成的干扰。 rCPV-PPRVH 疫苗接种还可以保护山羊免受有毒 CPV 的攻击。我们的结果表明，VNA 可以作为现场动物有效疫苗接种和免疫保护的依赖指标。我们研究中使用的重组 CPV 疫苗在新出现小反刍兽疫或尚未实施扑灭计划的国家可能是一种实用且有用的候选 DIVA 疫苗。 (C) 2010 Elsevier Ltd. 保留所有权利。
Recombinant capripoxvirus (CPV) is a promising candidate differentiating infected from vaccinated animals (DIVA) vaccine against peste-des-petits-ruminants (PPR). In order for recombinant CPV to be successfully used in the field, there should exist dependable indicators for quality control of vaccine products, surveillance and vaccination evaluation. Viral neutralization antibody (VNA) is correlated to protection against PPR and is a technically feasible indicator for this purpose. The immunogenicity of this vectored vaccine in goats and sheep, however, has not been fully evaluated. In this study, we generated two recombinant CPV viruses, rCPV-PPRVH and rCPV-PPRVF, that express PPR virus (PPRV) glycoproteins H and F, respectively. Vaccination studies with different dosages of recombinant viruses showed that rCPV-PPRVH was a more potent inducer of PPRV VNA than rCPV-PPRVF. One dose of rCPV-PPRVH was enough to seroconvert 80% of immunized sheep. A second dose induced significantly higher PPRV VNA titers. There was no significant difference in PPRV VNA responses between goats and sheep. Subcutaneous inoculation also induced a significant PPRV VNA response. PPRV VNA could be detected for over 6 months in more than 80% of vaccinated goats and sheep. Boost vaccination at 6-month intervals induced significant re-boost efficacy of PPRV VNA in goats and sheep. More over, two doses of rCPV-PPRVH could completely overcome the interference caused by pre-existing immunity to the CPV vaccine backbone in animals. Vaccination with rCPV-PPRVH also protected goats from virulent CPV challenge. Our results demonstrate that VNA can serve as a dependent indicator for effective vaccination and immune protection of animals in the field. The recombinant CPV vaccine used in our studies could be a practical and useful candidate DIVA vaccine in countries where PPR newly emerges or where stamp-out plans are yet to be implemented. (C) 2010 Elsevier Ltd. All rights reserved.